Portfolio News

 

   
May 2014
Kalvista Pharmaceuticals - Investment

SV Life Sciences Fund IV invested in Kalvista as part of a $5.2m Series A2 extension financing round. Kalvista is a Pharmaceutical and Ophthalmology company developing Plasma Kallikrein inhibitors.  


Team - Kate Bingham, Graham Boulnois

⇧ Back to top